Who We Are

MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI’s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk.

Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).

MSI has developed a superior oral formulation of the molecule with Strada™. We have completed  our HORIZON trial, a US, double-blind, randomized, placebo-controlled, Phase 2, adjunctive study in patients who have had an inadequate response to current anti-depressant therapy.

A long record of clinical use and a large body of credible, supporting research on Ademetionine indicates that Strada is generally well tolerated and clinically effective.  Strada™ is a proprietary formulation which has issued patents protecting it.